Moravick takes over as Ketchum healthcare head

Share this article:

Ketchum named Ann Moravick EVP and director, global healthcare and brand advocacy.

Moravick joins the company from Publicis Consultants PR, where she was US CEO.

She is charged with spearheading the growth and expanding the global reach of the agency's healthcare practice by bridging the work of its international offices, and reports to partners Dale Bornstein, director, global practices, and Barri Rafferty, director, New York.

The role of global healthcare director has been vacant at Ketchum since Mark Cater left it early last year to lead APCO Worldwide's healthcare practice.

Before joining Publicis, Moravick spent 18 years at Manning, Selvage & Lee, where she headed the firms London office and global healthcare practice and served as deputy managing director of the New York office. She is also a former board member of WOMMA, the Word of Mouth Marketing Association.

Bornstein said her “integrated approach to healthcare and brand advocacy will serve the evolving needs of our clients and further differentiate Ketchum's healthcare practice from others in the industry. With Ann's diverse experience, both in the US and in Europe, she will prove to be an asset to our healthcare clients as they navigate the global markets.”

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.